Sign in

ORIC on Nasdaq

Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.2 It is headquartered in San Francisco, United States.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerORIC on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Francisco, United States2
  • Incorporated inDE3
  • Business address240 E. Grand Ave., 2Nd Floor, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation2
  • LEI54930033FJRNEYBW0L252
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55953822

See how the biggest companies compare on our leaderboards

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by O vercoming R esistance I n C ancer .4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$143.0M in 2025+401% since 2019
-$150.0M-$100.0M-$50.0M02019: -$28.6M-$28.6M20192020: -$74.2M-$74.2M2020+160%2021: -$78.9M-$78.9M2021+6%2022: -$91.8M-$91.8M2022+16%2023: -$110.8M-$110.8M2023+21%2024: -$142.9M-$142.9M2024+29%2025: -$143.0M-$143.0M2025+0%
Net income56789-$129.5M in 2025+382% since 2019
-$150.0M-$100.0M-$50.0M02019: -$26.9M-$26.9M20192020: -$73.7M-$73.7M2020+174%2021: -$78.7M-$78.7M2021+7%2022: -$89.1M-$89.1M2022+13%2023: -$100.7M-$100.7M2023+13%2024: -$127.8M-$127.8M2024+27%2025: -$129.5M-$129.5M2025+1%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$109.8M$114.1M
General and administrative$33.2M$28.8M
Total operating expenses$143.0M$142.9M
Loss from operations-$143.0M-$142.9M
Other income, net$13.5M$15.0M
Net loss-$129.5M-$127.8M
Unrealized gain on investments$407.0K$121.0K
Comprehensive loss-$129.1M-$127.7M
Net loss per share, basic-$1.47-$1.83
Net loss per share, diluted-$1.47-$1.83
Weighted-average shares outstanding, basic87.8M shares69.7M shares
Weighted-average shares outstanding, diluted87.8M shares69.7M shares

Compare Oric Pharmaceuticals, Inc. with another company

Corporate structure

Oric Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Oric Pharmaceuticals, Inc.

  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G on Oric Pharmaceuticals, Inc., latest May 15, 2026
  • Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest May 15, 2026 (2 filings since Jun 4, 2025)
  • VIKING GLOBAL INVESTORS LP Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest May 15, 2026 (4 filings since Jan 30, 2024)
  • Venrock Healthcare Capital Partners III, L.P. Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest May 15, 2026 (5 filings since Feb 1, 2024)
  • Pfizer Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest May 12, 2026 (2 filings since Dec 29, 2022)
  • BlackRock Filed SCHEDULE 13G on Oric Pharmaceuticals, Inc., latest Jan 21, 2026 (8 filings since Feb 3, 2022)
  • COLUMN GROUP II, LP Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest Nov 17, 2025 (3 filings since Feb 11, 2022)
  • ALKEON CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest Nov 13, 2025 (4 filings since Feb 13, 2023)
  • Nextech Crossover I GP S.a r.l. Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest Aug 14, 2025 (3 filings since Jul 7, 2023)
  • SR ONE CAPITAL MANAGEMENT, LLC Filed SCHEDULE 13D/A on Oric Pharmaceuticals, Inc., latest Aug 14, 2025 (2 filings since Jun 5, 2025)
  • EcoR1 Capital, LLC Filed SCHEDULE 13G on Oric Pharmaceuticals, Inc., latest Aug 5, 2025 (5 filings since Feb 14, 2022)
  • Frazier Life Sciences Public Fund, L.P. Filed SCHEDULE 13G/A on Oric Pharmaceuticals, Inc., latest May 15, 2025 (2 filings since Jan 25, 2024)
  • Oric Pharmaceuticals, Inc. San Francisco, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Oric Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.1M9 Dec 31, 2025$10.4M9 Dec 31, 2024−3.2%
Accumulated depreciation$7.7M9 Dec 31, 2025$7.5M9 Dec 31, 2024+2.3%
Property and equipment, net$2.4M9 Dec 31, 2025$2.9M9 Dec 31, 2024−17.4%
Operating-lease assets (leased space)$6.7M9 Dec 31, 2025$8.4M9 Dec 31, 2024−20.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$45.7M9 Dec 31, 2025$59.4M9 Dec 31, 2024−23.1%
Marketable securities, current$235.8M9 Dec 31, 2025$196.6M9 Dec 31, 2024+20.0%
Marketable securities, non-current$110.8M9 Dec 31, 2025$09 Dec 31, 2024

Properties, in its own words

Our corporate headquarters are located in South San Francisco, California, where we lease 33,663 square feet of office, research and laboratory space, under a non-cancelable lease that expires in May 2028 with an option to renew for an additional one-year term. We are also under agreement to lease 13,041 square feet of office space and research and development space in San Diego, California through February 2028 with an option to renew for one period of two years. We believe that these existing facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.

Item 2 of the 10-K filed Feb 23, 2026.4

Leadership

Who has led Oric Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jacob Chacko2020–now

President

  1. Jacob Chacko2020–now

Chief financial officer

  1. Dominic Piscitelli2020–now
2025
Board members and other officers (10)

Timeline

  1. Aug 3, 20268-K Results of operations24
  2. Jul 30, 20268-K Executive or director change25
  3. Jun 22, 20268-K Executive or director change; Shareholder vote26
  4. May 4, 20268-K Results of operations27
  5. Mar 31, 20268-K Other events28
  6. Feb 23, 20268-K Results of operations29
  7. Feb 23, 20268-K Other events30
  8. Dec 8, 20258-K Other events31
  9. Nov 13, 20258-K Results of operations32
  10. Nov 13, 20258-K Regulation FD disclosure33
  11. Aug 12, 20258-K Results of operations; Exit or restructuring costs34
  12. Jun 13, 20258-K Shareholder vote35
  13. Apr 23, 2020New chief executive Jacob Chacko becomes CEO13
  14. Aug 29, 2014Founded Oric Pharmaceuticals, Inc. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.33) a share, on Nov 13, 2025.36

When it reported results

  1. Aug 3, 2026Reported quarterly or annual results24
  2. May 4, 2026Reported quarterly or annual results27
  3. Feb 23, 2026Reported quarterly or annual results29
  4. Nov 13, 2025Reported quarterly or annual results32
  5. Aug 12, 2025Reported quarterly or annual results34
  6. May 5, 2025Reported quarterly or annual results37
  7. Feb 18, 2025Reported quarterly or annual results38
  8. Nov 12, 2024Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

280 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 93 insider forms, 54 large holders, 3 private raises, 62 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 1, 2026144 EDGAR
  3. Oct 1, 2026144 EDGAR
  4. Sep 29, 20264 EDGAR
  5. Sep 25, 20264 EDGAR
  6. Aug 28, 20264 EDGAR
  7. Aug 26, 2026144 EDGAR
  8. Aug 3, 202610-Q EDGAR
  9. Aug 3, 20268-K EDGAR
  10. Jul 30, 2026S-8 EDGAR
  11. Jul 30, 20268-K EDGAR
  12. Jul 28, 20264 EDGAR
  13. Jul 8, 20264 EDGAR
  14. Jul 6, 2026144 EDGAR
  15. Jul 6, 2026144 EDGAR
  16. Jun 22, 20268-K EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 15, 2026SCHEDULE 13G/A EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 15, 2026SCHEDULE 13G EDGAR

The 280 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

51 open-market trades by officers, directors and large owners since October 2021: 9 buys and 42 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Piscitelli DominicChief Financial OfficerSale13,400$13.53$181.3KForm 4
Sep 24, 2026Piscitelli DominicChief Financial OfficerSale600$13.51$8.1KForm 4
Aug 26, 2026Piscitelli DominicChief Financial OfficerSale77,000$13.69$1.1MForm 4
Jul 24, 2026Heyman Richard A.DirectorSale13,100$12.02$157.5KForm 4
Jul 6, 2026Heyman Richard A.DirectorSale300$12.00$3.6KForm 4
Feb 24, 2026Piscitelli DominicChief Financial OfficerSale52,000$13.51$702.5KForm 4
Jan 16, 2026Heyman Richard A.DirectorSale6,700$12.00$80.4KForm 4
Dec 16, 2025Piscitelli DominicChief Financial OfficerSale10,720$9.06$97.1KForm 4
Dec 16, 2025Chacko JacobPRESIDENT AND CEOSale33,374$9.06$302.4KForm 4
Dec 16, 2025Multani Pratik SChief Medical OfficerSale10,720$9.06$97.1KForm 4
Oct 6, 2025Piscitelli DominicChief Financial OfficerSale11,000$14.52$159.7KForm 4
Oct 6, 2025Chacko JacobPRESIDENT AND CEOSale37,461$12.32$461.5KForm 4
Oct 1, 2025Chacko JacobPRESIDENT AND CEOSale53,001$12.05$638.7KForm 4
Sep 30, 2025Chacko JacobPRESIDENT AND CEOSale34,538$12.01$414.8KForm 4
Sep 22, 2025Chacko JacobPRESIDENT AND CEOSale125,000$10.80$1.4MForm 4
Jul 1, 2025Piscitelli DominicChief Financial OfficerSale20,000$10.05$201.0KForm 4
Jun 24, 2025Piscitelli DominicChief Financial OfficerSale32,466$10.50$340.9KForm 4
Jun 23, 2025Piscitelli DominicChief Financial OfficerSale1,034$10.00$10.3KForm 4
Jun 23, 2025You AngieDirectorBuy1,403$9.43$13.2KForm 4
Jun 20, 2025You AngieDirectorBuy26,597$9.39$249.7KForm 4

All 51 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Jacob M. ChackoM.D.47$657.5K$5.6M57
2025Pratik MultaniM.D.59$513.3K$2.3M57
2025Dominic Piscitelli52$482.9K$2.2M57
2024President and Chief Executive Officer$627.3K$5.3M57
2024Chief Medical Officer$493.6K$2.2M57
2024Chief Financial Officer$458.1K$2.2M57

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 29, 2025Raised $125 million in a private offering of equity Form D: 15 investors so far Form D
  2. Jan 23, 2024Raised $125 million in a private offering of equity Form D: 10 investors so far Form D
  3. Jun 27, 2023Raised $85 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nextech Invest Ltd.7,162,637$77.6M3.7%No change
BlackRock, Inc.6,823,973$73.9M0.0%+839,421
EcoR1 Capital, LLC6,728,116$72.9M3.6%No change
Viking Global Investors LP5,126,762$55.5M0.2%−697,771
State Street Corp4,894,000$53.0M0.0%+1,191,804
SR One Capital Management, LP4,615,384$50.0M4.8%+100,455
Venrock Adviser, LLC4,319,765$46.8M1.4%No change
NEA Management Company, LLC4,118,621$44.6M2.8%No change
Vanguard Capital Management LLC3,951,169$42.8M0.0%+264,162
AIHC Capital Management Ltd3,828,460$41.5M39.8%+1,368,909
Alkeon Capital Management LLC3,739,096$40.5M0.2%−765,000
Column Group LLC3,540,777$38.3M43.5%No change
Siren, L.L.C.2,998,192$32.5M0.7%No change
Fmr LLC2,635,475$28.5M0.0%+201,395
Citadel Advisors LLC2,595,299$28.1M0.0%+172,558
Goldman Sachs Group Inc2,451,796$26.6M0.0%+976,084
Geode Capital Management, LLC2,090,089$22.6M0.0%+251,288
First Turn Management, LLC2,017,284$21.8M2.3%No change
Orbimed Advisors LLC2,015,000$21.8M0.4%−678,929
Integral Health Asset Management, LLC1,900,000$20.6M0.8%+500,000
Mpm Bioimpact LLC1,882,162$20.4M1.2%+78,217
Vivo Capital, LLC1,848,786$20.0M1.8%No change
Dimensional Fund Advisors LP1,801,399$19.5M0.0%+330,109
Franklin Resources Inc1,797,377$19.5M0.0%+344,542
Morgan Stanley1,794,020$19.4M0.0%+111,497

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Oric Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROric Pharmaceuticals, Inc.1
  • CIK0001796280
  • Employer ID (EIN)47-17871574
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address240 E. Grand Ave., 2Nd Floor, South San Francisco, CA 940801
  • Phone(650) 388-56001
  • Shares outstanding103,652,656 as of Jul 27, 202611
  • Public float$862.4M as of Jun 30, 20254
  • AuditorKPMG LLP, San Diego, California PCAOB ID 185; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 13, 20191
  • Filings421 in all: 4 (147), 8-K (64), SC 13G/A (23), 144 (21), 10-Q (20), SC 13G (17), 3 (15), SCHEDULE 13G/A (14)1
    All 40 form types

    CORRESP (11), S-8 (8), UPLOAD (8), 10-K (6), DEF 14A (6), DEFA14A (6), EFFECT (6), SCHEDULE 13G (5), ARS (4), SC 13D/A (4), 4/A (3), 424B5 (3), D (3), S-3 (3), 424B4 (2), DRS (2), S-1 (2), S-1/A (2), S-1MEF (2), S-3ASR (2), 424B3 (1), 8-A12B (1), CERT (1), DRS/A (1), DRSLTR (1), POS AM (1), POSASR (1), SC 13D (1), SC TO-I (1), SC TO-I/A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2026
    Quarterly report (10-Q) Aug 3, 2026
    Proxy statement (DEF 14A) Apr 28, 2026
    Latest 8-K (8-K) Aug 3, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareORICThe Nasdaq Global Select Market

From the cover page of the 10-K filed Feb 23, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Oric Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Feb 23, 2026: 70 risks under these headings, as written.4

  • Risks related to our financial position and need for additional capital
  • Risks related to development and commercialization of our product candidates
  • Risks related to regulatory, legal and other compliance matters
  • Risks related to employee matters and management of our growth
  • Risks related to intellectual property
  • Risks related to dependence on third parties
  • Risks related to the securities markets and ownership of our common stock
  • We have a limited operating history, have not initiated or completed any large-scale or pivotal clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability.
  • We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future.
  • Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the development and commercialization of our product candidates.
  • We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
  • Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others.
The other 65 risks
  • Risks related to the development and commercialization of our product candidates
  • We are substantially dependent on the success of our product candidates, rinzimetostat and enozertinib. If we are unable to complete development of, obtain approval for and commercialize our product candidates for one or more indications in a timely manner, our business will be harmed.
  • In addition to rinzimetostat and enozertinib, our prospects depend in part upon developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.
  • The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
  • The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results.
  • Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
  • The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.
  • Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Adverse results of clinical trials conducted by third parties investigating the same class of product candidates as us in the same or different territories or indications could adversely affect our development of such product candidate.
  • Reports of side effects or safety concerns in other companies’ clinical trials of the same or similar class of products or of products sharing the same mechanism of action as our product candidates could delay or prevent us from obtaining regulatory approval for our product candidates or negatively impact public perception and market acceptance of our product candidates.
  • If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.
  • Our operations and financial results could be adversely impacted by global pandemics or other public health emergencies in the United States and the rest of the world.
  • If we are unable to successfully develop any required companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, we may not realize the full commercial potential of our product candidates.
  • We may develop our programs in combination with other therapies, which exposes us to additional risks.
  • We have limited resources and are focusing our efforts on developing rinzimetostat and enozertinib. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.
  • We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.
  • The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production or supply chain. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
  • The market opportunities for our product candidates we develop, if approved, may be limited to certain smaller patient subsets.
  • We may not be successful in augmenting our product pipeline through acquisitions and in-licenses.
  • Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
  • Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.
  • Information obtained from expanded access studies may not reliably predict the efficacy of our product candidates in our clinical trials and may lead to adverse events that could materially harm our business.
  • Risks related to regulatory approval and other legal compliance matters
  • We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our product candidates.
  • The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining FDA approval of a diagnostic test, we will not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired.
  • We may seek Fast Track designation from the FDA for one or more of our product candidates. Even if one or more of our product candidates receive Fast Track designation, we may be unable to obtain or maintain the benefits associated with the Fast Track designation.
  • We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.
  • We may face difficulties from changes to current regulations and future legislation.
  • Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • If we fail to comply with other U.S. healthcare laws and compliance requirements, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
  • Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
  • Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business.
  • Risks related to employee matters, managing our growth and other risks related to our business
  • Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
  • Our strategic pipeline prioritization and the associated workforce reduction announced in August 2025, may not result in anticipated cost savings and could disrupt our business.
  • If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.
  • In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
  • Our operations are vulnerable to interruption by natural disasters, extended power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business.
  • Our Chief Business Officer was sued by the Securities and Exchange Commission for insider trading on a matter unrelated to ORIC.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.
  • Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions.
  • A variety of risks associated with contracting with foreign third parties or marketing our product candidates internationally could materially adversely affect our business.
  • We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, including the ongoing international military conflicts.
  • Inflation and market volatility may adversely affect us by increasing our costs.
  • Risks related to our intellectual property
  • Our success depends on our ability to protect our intellectual property and our proprietary technologies.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • We may be involved in lawsuits to protect or enforce our patents or our licensors’ patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or our licensors’ patents could be found invalid, unenforceable or not infringed if challenged in court.
  • Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
  • Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
  • Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors.
  • Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we do not obtain patent term extension for our product candidates, our business may be materially harmed.
  • We may not be able to protect our intellectual property rights throughout the world.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57